The p53 mutation rates of pathological stage I and II–IV lung adenocarcinomas were 32% (18 of 57) and 44% (29 of 66), respectively, not significantly different by Fisher’s exact test (p=0.19). This evidence concerns the gene TP53 and lung adenocarcinoma.